Tin tức & Cập nhật

Neoadjuvant immunotherapy delivers in cisplatin-ineligible bladder cancer
Neoadjuvant immunotherapy delivers in cisplatin-ineligible bladder cancer
03 Mar 2023
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
03 Mar 2023 bởiStephen Padilla

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.

Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
03 Mar 2023
FDRS variables predict Alzheimer's, dementia in HF, AF patients
FDRS variables predict Alzheimer's, dementia in HF, AF patients
03 Mar 2023